Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
Despite significant advances in colorectal cancer screening and treatment, systemic inequities continue to drive higher incidence and mortality rates among Black Americans compared with White individuals, according to a recent review.
Despite significant advances in colorectal cancer screening and treatment, systemic inequities continue to drive higher incidence and mortality rates among Black Americans compared with White individuals, according to a recent review.
Despite national declines in colorectal cancer deaths, a 20-year study finds Black men and residents of Southern and Midwestern states continue to face disproportionately high mortality rates.
Despite national declines in colorectal cancer deaths, a 20-year study finds Black men and residents of Southern and Midwestern states continue to face disproportionately high mortality rates.
